Bryan Smith has served as general counsel, corporate secretary and chief compliance officer of Eledon Pharmaceuticals since April 2021. In this role as the company’s first-ever general counsel, responsible for the company’s legal, compliance, intellectual property and corporate governance functions. Prior to joining Eledon, Smith was general counsel, corporate secretary and chief compliance officer of Urovant Sciences from April 2018 to April 2021. During his time at Urovant, Smith led the company through its initial public offering, in which the company raised $140M in gross proceeds and listed on the Nasdaq stock exchange, through its eventual sale for $584M in total equity value to Sumitomo Dainippon Pharma. Urovant also received U.S. Food and Drug Administration approval for its lead urology drug and launched the drug commercially during his tenure.

From August 2011 to April 2018, Smith was an associate vice president and senior counsel at Allergan, where he was chief counsel to the company’s urology, neurology, aesthetics and dermatology business units. Smith also led Allergan’s anti-counterfeiting and anti-diversion efforts in close cooperation with the U.S. FDA’s Office of Criminal Investigations and other federal, state and international law enforcement agencies. Prior to joining Allergan, Smith was a litigator at Gibson, Dunn & Crutcher LLP.

Smith received his BA in political science from Brigham Young University and his JD from the University of Southern California Gould School of Law. After graduating from law school, Smith was a law clerk to the Hon. Cormac J. Carney in the U.S. District Court for the Central District of California.